DOCSLIB.ORG

A. S. Joshi & Company

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A. S. Joshi & Company // Shree Ganeshay Namah // A. S. JOSHI & COMPANY 813. Topiwala Center, Opp Railway Station Goregaon (W), Mumbai – 400 062, INDIA Tel – 022 28768362 E-mail : [email protected] Visit : www.joshichem.com -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Active Pharmaceuticals Ingredients(API’s) & Excipients – Importer, Exporter, Distributers -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ Active Pharmaceutical Ingredients & Excipients Product List:- Adapalene Asenapine Bezafibrate Carbocisteine Clobetasol Adefovir Dipivoxil Asparaginase Bicalutamide Carboplatin Clobetasol Propinate Adenosine Astemizole Bimatoprost Carboprost Clofazimine Albendazole Atazanavir Bisacodyl Carisoprodol Clomiphene Alendr onate At enolol Bi soprolol Ca rvedilol Clo mipramine Alfacalcidol Atomoxetine Hcl Bleomycin Celecoxib Clonidine Alfuzosin Atorvastatin Bortezomib Celiprolol Clopamide Aliskiren Atracurium Bosentan Cephalexin Clopidogrel Allopurinol Atracurium Besylate Brimonidine Cetirizine Clotrimazole Allylestrenol Atropine Bromocriptine Cetrimide Dacarbazine Alpro stadil Aurano fin Buclizine Chl orpropamide D actinomycin Alt eplase Azatadine Maleate Budes onide Chl orthalidone D alteparin A mantadine Azathi oprine Bupiva caine Chl orzoxazone D anazol Ambroxol Bacampicillin Buprenorphine Chymotrypsin Dapoxetine Hcl A mifostin Ba clofen Bupro pion Chy motrypsin Alfa D arbepoetin Alfa A mifostine Ba lofloxacin Buse relin Ci clesonide D arifenacin Amikacin Balsalazide Buspirone Ciclopirox Daunorubicin Amiloride Bambuterol Butenafine Ciclosporin Demeclocycline Aminocaproic Acid Bamipine Butorphanol Cilnidipine Desloratadine Aminophylline Beclomethasone Cabergoline Cilostazol Dexamethasone A miodarone Be miparin Sodium Caf feine Ci metidine D exibuprofen A misulpride Be nazepril Ca lamine Cinch ocaine Hcl D extromethorphan Dextromethorphen Amitriptyline Bendamustine HCL Calcipotriol Cinitapride HBr A mlodipine Be nfotiamine Ca lcitonin- Salmon Cinnarizi ne Diacerein A mrinone Be nidipine Ca lcitriol Cipr ofloxacin D ibucaine Anastr ozole Be nserazide Ca mylofin Cis platin D iclofenac Apraclonidine Benzalkonium Chloride Candesartan Citalopram Diclofenac potassium Apro tinin Be nzocaine Ca pecitabine Cit icoline D icloxacillin Ardepa rin Be nzonatate Ca preomycin Cl arithromycin D icyclomine Aripipra zole Be nzydamine Ca psaicin Cl avulanate D idanosine Ar modafinil Be tahistine Ca ptopril Cl emastine D ienestrol Artemether Betamethasone Carbamazepine Clindamycin Dimethicone Artesunate Betaxolol Ophthalmic Carbidopa Clioquinol Diphenhydramine Ascorbic Acid (Vitamin C) Bethanechol Carbimazole Clobazam Diphenoxylate // Shree Ganeshay Namah // A. S. JOSHI & COMPANY 813. Topiwala Center, Opp Railway Station, Goregaon (W), Mumbai – 400 062, INDIA Tel – 022 28768362 E-mail : [email protected] Visit : www.joshichem.com -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Active Pharmaceuticals Ingredients(API’s) & Excipients – Importer, Exporter, Distributers -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ Active Pharmaceutical Ingredients & Excipients Product List:- Dipivefrin Esomeprazole FURSULTIAMINE HCl Ibuprofen Lercanidipine Esomeprazole Dipyridamole magnesium trihydrate Fusidic acid Idarubicin HCL Letrozole D isopyramide Estradiol Ga lantamine Hbr Ido xuridine L eucovorin D isulfiram E thambutol Ga nciclovir sodium Ifo sfamide L eucovorin Sodium D ivalproex E thambutol HCl Ga tifloxacin I matinib Mesylate L euprolide Dobutamine Etodolac Gefitinib Imipenem Levalbuterol HCl Docetaxel Etoposide Gemcitabine hcl Indapamide Levamisole Docusate Etoricoxib Gemfibrozil Indinavir LEVAMISOLE Domperidone Exemestane Gentamycin Indomethacin Levetiracetam Don epezil Ez etimibe G estodene I odixanol L evocetirizine Dop amine HCL Fa mciclovir Gi meracil I ohexol L evodopa Dorzolamide Famotidine Ginkgo Biloba Iopamidol Levofloxacin Hcl Dothiepin Febuxostat Gleevec Iopromide Levothyroxine Sodium D oxofylline Fe lbamate Gl ibenclamide I oversol L idocaine Hcl D oxorubicin Fe lodipine Gl iclazide Ipratr opium L incomycin Hcl D oxycycline Fe nbendazol Gl iclazide Irbesa rtan L inezolid Doxylamine FENFLURAMINE Glimepiride Irinotecan Liothyronine Drotaverine FENOFIBRATE Glimepiride Isoniazid Lisinopril Duloxetine Hcl Fenofibric Acid Glucosamine Isoprenaline Lomefloxacin Dutasteride Fexofenadine HCL Glucosamine Sulfate Isosorbide Lomustine Dy drogesterone Finast eride G LYCOPYRROLATE Is otretinoin L operamide Hcl Eb astine FL AVOXATE HCL G oserelin acetate Is oxsuprine L oratadine Ebastine Flubendazole Guaifenesin Itopride Lorazepam Econazole Fluconazole Halcinonide Itraconazole Lornoxicam Hal obetasol Efavirenz Fludarabine phosphate Propionate Ivabradine Losartan Efa virenz Flunari zine Haloperidol Iv ermectin L ovastatin Embramine Fluoxetine HCL Halothane Kanamycin Lumefantrine Emtricitabine- Fluphenazine HCL Hamycin Ketoconazole Mafenide Enalapril Flurbiprofen Heparin sodium Ketoprofen Mannitol Enanthate Flutamide Hydrochlorothiazide Ketorolac Mebendazole Fluticasone Enoxaparin proprionate Hydrocortisone Ketotifen Mebeverine Ent acapone Fluvasta tin Hy droquinone L acidipine M eclizine HCl Ent ecavir Fluv oxamine Hy droxy Progesterone L acosamide M eclofenoxate HCL Ep alrestat F ormestane Hy droxychloroquine L afutidine M ecobalamin Epirubicin hcl Formoterol Hydroxycobalamin Lamivudine Medroxyprogesterone Ertapenem sodium Formoterol Fumarate Hydroxyurea Lamotrigine Mefenamic Acid Erythromycin Fosfomycin Hyoscine Lansoprazole Mefloquine HCL Erythromycin Fulvestrant Hypromellose Latanoprost Megestrol acetate Es molol Furosem ide Iban dronate L eflunomide M eglumine // Shree Ganeshay Namah // A. S. JOSHI & COMPANY 813. Topiwala Center, Opp Railway Station, Goregaon (W), Mumbai – 400 062, INDIA. Tel – 022 28768362 E-mail : [email protected] Visit : www.joshichem.com -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Active Pharmaceuticals Ingredients(API’s) & Excipients – Importer, Exporter, Distributers -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ Active Pharmaceutical Ingredients & Excipients Product List:- Pramiracetam Melatonin Nadifloxacin Oxethazaine Sulphate Rifaximin M elitracen Nadro parin Ox iconazole Prasugrel Ri sedronate Sodium Meloxicam Nalidixic Acid Oximetazoline Prazosin HCL Risperidone Melphalan HCL Naloxone Oxybutynin Chloride Prednisolone Acetate Ritodrine M emantine HCL Naltr exone Ox yclozanide P regabalin Ri tonavir M enadione Nandrol one Ox ymetazoline HCL P regnenolone Ri vastigmine Menotropins Naphazoline Oxymetholone Procarbazine HCL Rivastigmine Tartrate Mephenesin Naproxen Oxytetracycline HCL Prochlorperazine Ropinirole M ercaptopurine Nat eglinide P aclitaxel P rocyclidine R opivacaine HCL M eropenem Nebi volol P aliperidone P rogesterone R osiglitazone Maleate M estanolone Nedaplat in P alonosetron P roglumide R osuvastatin Metadoxine Nefazodone HCL Pamidronate Disodium Promethazine Roxatidine Metaxalone Nelfinavir Pancreatin Propofol Rupatadine Propranolol Metenolone Acetate Neomycin Sulphate Pancuronium Bromide Hydrochloride Salbutamol sodium M ethacycline Ne ostigmine P antoprazole Sodium Propyphenazone Sal meterol Methandienone Nepafenac Papaverine Protamine sulphate Scopolamine HBR Methandrostenolone Netilmicin Sulfate Parecoxib Quetiapine Secnidazole Methotrexate Nevirapine Paroxitine Quinapril hcl Selegiline hcl M ethyl Salicylate Niacin P arvastatin Sodium Qu inine sulphate Se rtaconazole Nitrate M ethylcobalamine Nic orandil P efloxacin Qu inacrine Se rtraline hcl Methyldopa Nifedipine Pemetrexed Quiniodochlor Sildenafil Citrate Methylprednisolone Nimesulide Pentoxifylline Quetiapine Simvastatin Metoclopramide Nimodipine Perindopril Rabeprazole SINCALIDE Metoprolol Tartrate Nistatin Phenazopyridine HCL Racecadotril Sitagliptin P hentolamine Metronidazole Octreotide Mesylate Raloxifene HCL Sodium fusidate M ianserin O estradiol Phenylephrine Ra ltitrexed S odium Hyaluronate Miconazole Nitrate Ofloxacin Phenylpropanolamine Ramipril Sodium Nitroprusside M ifepristone Ol anzapine P henytoin sodium Ra nitidine HCL S odium Picosulphate S odium Minoxidil Olmesartan Phosphomycin Ranolazine Sulphacetamide M irtazapine Ol opatadine P hytomenadione Ra pamycin Sparfl oxacin M isoprostol O meprazole P ilocarpine Re bamipide Spec tinomycin HCL M itomycin On dansetron HCL P ioglitazone Re boxetine Spiram ycin Mitoxantrone HCL Orlistat Pipemidic Acid Repaglinide Spironolactone Mivacurium Chloride Ornidazole Piperacillin Residronate sodium Stanozolol Moclobemide Oteracil potassium Piroxicam Retinol Acetate Stavudine Modafinil Oxacillin Polymyxin B Sulphate Reviparin Sodium Streptomycin Sulphate Mon telukast sodium Ox aliplatin Po lymyxin B1 Riba virin Str ontium Chloride M oxalactam sodium Ox androlone Po lymyxin E Rif abutin Succin ylcholine Moxifloxacin HCL Oxcarbazepine Pramipexole Rifampicin Sucralfate
Load more

Recommended publications
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • (Esi Scheme) Laxminagar, Ajmer Road, Jaipur-302006
    DIRECTORATE, MEDICAL & HEALTH SERVICES, (E.S.I. SCHEME) LAXMINAGAR, AJMER ROAD, JAIPUR-302006 Tel/Fax 0141-2223572,www.health.rajasthan.gov.in/esi E-Mail [email protected],[email protected] Ref. No. F434/ESI/Store/LabEmp/2017/5540 Dated:01/11/2017 E- Tender Document For “E- Tender forAnalysis of Drugs, Cotton, Gauzes, Bandage & Other items” For The Office of the Director cum Ex-officio Dy. Secretary, Medical & Health Services ESI Scheme Rajasthan, Laxmi Nagar, Ajmer Road, Jaipur & attached ESIS Institutions in Rajasthan ( for the period of two years from the date of award. ) ( Non-transferable ) Price of Tender Document Rs. 2000/- Last date & time of submission of Technical & Financial Bids is 11.12.17 at 1:30 pm Date & time of online opening of Technical Bid is 11.12.17 at 3:00 pm Visit Us At http://sppp.raj.nic.in, www.dipronline.org, http://eproc.rajasthan.gov.in, www.health.rajasthan.gov.in/esi Our Address: DIRECTORATE, MEDICAL & HEALTH SERVICES, (E.S.I. SCHEME) LAXMINAGAR, AJMER ROAD, JAIPUR-302006 1/71 DIRECTORATE, MEDICAL & HEALTH SERVICES, (E.S.I. SCHEME) LAXMINAGAR, AJMER ROAD, JAIPUR-302006 Tel/Fax 0141-2223572,www.health.rajasthan.gov.in/esi E-Mail [email protected],[email protected] Ref.No.F434/ESI/Store/LabEmp/2017/ 5540 Dated:01/11/2017 E-bids in two separate bids (Technical & Financial) for the Empanelment of Analytic Testing Laboratories For The Test and Analysis of drugs, cotton, bandage, gauze & other items. Brief Details of E-Tender Estimated Cost : Rs 50 lacs EMD (Bid Security)Rs 100000/- RISL processing fees Rs 1000/- Cost of the Tender Document Rs 2000/- Performance Security 5% of contract value Services Required:- The service of analysis of drugs, cotton, gauze, bandages & other items are required in the office of the Director cum Ex- officio Dy.
    [Show full text]
  • MMC International BV
    M.M.C. International Steroid Substances Steroid Test A Colour Steroid Test B Colour Steroid Test B Colour with UV Light Stanozolol/ Oxandrolone Test Clenbuterol/ Oxymetholone Test Ephedrine Test Alfadolone Orange Yellow Nil - - - Androsterone Orange Yellow White - - - Beclometasone Brown–yellow Orange Nil - - - Betamethasone Orange–brown Pink–Orange Nil - - - Boldenone Base (Equipoise, Ganabol) (pure powder) Warm red after 2 min. Dark Orange after 2 min. Bright Light Orange - - - Boldenone Undecanoate (oil) Dark brownish-red Dark Red Bright Light Orange - - - Boldenone Undecylenate (oil) Orange - Light Brown Dark Orange → Brown Bright Light Orange-Yellow - - - Carbenoxolone (CBX) Orange Yellow Yellow - - - Cholesterol Violet Orange White - - - Clenbuterol (Spiropent, Ventipulmin) - - - - Purple - Dark brown with yellow-green on the Dark brown with yellow-green on the Clomiphene (Androxal, Clomid, Omifin) Nil Dark brown to black No reaction Dark brown to black sides of the ampoule sides of the ampoule Cortisone Orange Yellow Green - - - Desoxycortone Blue–black Yellow Yellow - - - Dexamethasone Yellow Orange–pink Nil - - - Dienestrol Yellow Orange–red Nil - - - Diethylstilbestrol (DES) Orange (→yellow–green) Nil - - - Dimethisterone Brown–green Orange–red Yellow - - - Drostanolone Propionate (Masteron) (oil) Bright green Yellow-Orange Orange - - - Dydrogesterone (Duphaston) - Orange Green-Yellow - - - Enoxolone Orange Yellow Green-Yellow - - - Ephedrine (also for Pseudo- and Nor-Ephedrine) - - - - - Orange Estradiol (Oestradiol) Orange
    [Show full text]
  • Toiminta Unita on Ulla La Mungukurti |
    TOIMINTAUNITA USON 20180071390A1ULLA LA MUNGUKURTI | ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2018/ 0071390 A1 PATEL et al. (43 ) Pub . Date : Mar . 15 , 2018 ( 54 ) COMPOSITIONS OF PHARMACEUTICAL A61K 9 / 06 (2006 .01 ) ACTIVES CONTAINING DIETHYLENE A61K 9 /00 (2006 .01 ) GLYCOL MONOETHYL ETHER OR OTHER A61K 31 /573 ( 2006 .01 ) ALKYL DERIVATIVES A61K 31/ 565 ( 2006 .01 ) A61K 31/ 4439 ( 2006 . 01 ) ( 71 ) Applicant : THEMIS MEDICARE LIMITED , A61K 31 / 167 ( 2006 . 01 ) Mumbai (IN ) A61K 31 / 57 (2006 . 01) (52 ) U . S . CI. (72 ) Inventors : Dinesh Shantilal PATEL , Mumbai CPC .. .. .. A61K 47 / 10 ( 2013 . 01 ) ; A61K 9 /4858 ( IN ) ; Sachin Dinesh PATEL , Mumbai ( 2013 .01 ) ; A61K 9 /08 ( 2013 .01 ) ; A61K 9 / 06 ( IN ) ; Shashikant Prabhudas ( 2013 .01 ) ; A61K 9 / 0014 ( 2013 .01 ) ; A61K KURANI, Mumbai ( IN ) ; Madhavlal 31/ 573 ( 2013 .01 ) ; A61K 31 /57 ( 2013 .01 ) ; Govindlal PATEL , Mumbai ( IN ) A61K 31/ 565 ( 2013 .01 ) ; A61K 31 /4439 (73 ) Assignee : THEMIS MEDICARE LIMITED , ( 2013 .01 ) ; A61K 31/ 167 ( 2013 .01 ) ; A61K Mumbai (IN ) 9 /0048 ( 2013 .01 ) ; A61K 9 /0019 (2013 .01 ) ( 57 ) ABSTRACT (21 ) Appl. No .: 15 / 801, 390 The present invention relates to pharmaceutical composi tions of various pharmaceutical actives, especially lyophilic ( 22 ) Filed : Nov . 2 , 2017 and hydrophilic actives containing Diethylene glycol mono ethyl ether or other alkyl derivatives thereof as a primary Related U . S . Application Data vehicle and /or to pharmaceutical compositions utilizing (62 ) Division of application No. 14 /242 , 973 , filed on Apr. Diethylene glycol monoethyl ether or other alkyl derivatives 2 , 2014 , now Pat. No. 9 , 827 ,315 .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL Et Al
    US 20140296.191A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL et al. (43) Pub. Date: Oct. 2, 2014 (54) COMPOSITIONS OF PHARMACEUTICAL (52) U.S. Cl. ACTIVES CONTAINING DETHYLENE CPC ............... A61K 47/10 (2013.01); A61 K9/0019 GLYCOL MONOETHYLETHER OR OTHER (2013.01); A61 K9/0048 (2013.01); A61 K ALKYL DERVATIVES 45/06 (2013.01) USPC ........... 514/167: 514/177; 514/178: 514/450; (71) Applicant: THEMIS MEDICARE LIMITED, 514/334: 514/226.5: 514/449; 514/338; Mumbai (IN) 514/256; 514/570; 514/179; 514/174: 514/533; (72) Inventors: Dinesh Shantilal PATEL, Mumbai (IN); 514/629; 514/619 Sachin Dinesh PATEL, Mumbai (IN); Shashikant Prabhudas KURANI, Mumbai (IN); Madhavlal Govindlal (57) ABSTRACT PATEL, Mumbai (IN) (73) Assignee: THEMIS MEDICARE LIMITED, The present invention relates to pharmaceutical compositions Mumbai (IN) of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl (21) Appl. No.: 14/242,973 ether or other alkyl derivatives thereofas a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene (22) Filed: Apr. 2, 2014 glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or as a solvent system in preparation of Such (30) Foreign Application Priority Data pharmaceutical compositions. The pharmaceutical composi Apr. 2, 2013 (IN) ......................... 1287/MUMA2013 tions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formu Publication Classification lations containing such pharmaceutical actives and are Suit able for use as injectables for intravenous and intramuscular (51) Int. Cl. administration, as well as for use as a preformed solution/ A647/ (2006.01) liquid for filling in and preparation of capsules, tablets, nasal A6 IK 45/06 (2006.01) sprays, gargles, dermal applications, gels, topicals, liquid oral A6 IK9/00 (2006.01) dosage forms and other dosage forms.
    [Show full text]
  • Pharmacological Treatment Options for Alcohol Use Disorder*
    Dusunen Adam The Journal of Psychiatry and Neurological Sciences 2015;28:283-300 Editorial / Editoryal DOI: 10.5350/DAJPN20152804001 Pharmacological Treatment Cuneyt Evren1, Muge Bozkurt2 1Assoc. Prof. Dr., 2Psychiatrist, Bakirkoy Training and Options for Alcohol Use Research Hospital for Psychiatry, Neurology and Neurosurgery, Alcohol and Drug Research, Treatment and Training Center (AMATEM), Disorder* Istanbul - Turkey Address reprint requests to / Yazışma adresi: Assoc. Prof. Dr. Cuneyt Evren, Bakirkoy Training and Research Hospital for Psychiatry, Neurology and Neurosurgery, Alcohol and Drug Research, Treatment and Training Center (AMATEM), Istanbul, Turkey Phone / Telefon: +90-212-409-1515/2111, Fax / Faks: +90-212-409-1590, E-mail address / Elektronik posta adresi: [email protected] *Abridged version of the “Therapeutic Guideline for Alcohol Use Disorder” prepared by the Working Group Therapeutic Guideline for Alcohol Use Disorder. PHARMACOLOGICAL TREATMENT assess information obtained from studies regarding OPTIONS FOR ALCOHOL USE DISORDER drug treatments used in clinical practice today, which are summarized in Table 1. However, when examining Alcohol Use Disorder (AUD) and other alcohol- study results for pharmacological treatments, we related health problems are a significant public health immediately have to remember that all of those issue all over the world. The World Health Organization (WHO) reports that each year 3.3 million people lose Table 1: Drugs used for the therapy of alcohol use their lives due to harmful alcohol use, with 5.9% of all disorder (AUD) deaths being related to alcohol consumption (1). It has Drugs for AUD approved in Turkey been estimated that in 2010, the economic burden of Disulfiram Naltrexone alcohol-related costs was 155.8 billion Euro, of which Acamprosate 60% were connected to alcohol addiction (2).
    [Show full text]
  • SEAC) Held on 01/10/2019 at Committee Room, Gujarat Pollution Control Board, Sector 10A,Gandhinagar
    Minutes of the 554 th meeting ofthe State Level Expert Appraisal Committee (SEAC) held on 01/10/2019 at Committee Room, Gujarat Pollution Control Board, Sector 10A,Gandhinagar. The 554 th meeting of the State Level Expert Appraisal Committee (SEAC) was held on 1st October 2019 at Committee Room, Gujarat Pollution Control Board, Sector 10A, Gandhinagar. Following members attended the meeting: 1. Dr. Dinesh Misra, Chairman, SEAC 2. Shri S. C. Srivastav, Vice Chairman, SEAC 3. Shri Rajesh. I. Shah, Member, SEAC 4. Shri V. N. Patel, Member, SEAC 5. Dr. V. K. Jain, Member, SEAC 6. Shri A. K. Mule, Member, SEAC The regular agenda of Appraisal, Screening & Scoping/ToR, Reconsideration cases were taken up. The Committee considered the applications made by project proponents, additional details submitted as required by the SEAC/SEIAA and details furnished in the Form-1, PFR, EIA-EMP reports. Proposal No. Name and Address of the Unit Remarks 04 SIA/GJ/IND2/29059/2017 M/s. Dev Dyechem Industries EC – Plot No. C-1/324, Phase-I & II GIDC – Reconsideration Naroda, Ahmedabad. • PP remained absent in the EC – Appraisal presentation held on 01/10/2019. • After detailed discussion, Committee decided to defer the proposal and consider the same in one of the upcoming meeting of SEAC. 05 SIA/GJ/IND2/29678/2018 M/s. Apex Pharma EC – C-298/2/4, Saykha Industrial Estate, Reconsideration Saykha, Ta- Vagra, Dist -Bharuch. Category of the unit: 5(f) Project status: New • Project proponent (PP) submitted online application vide no. SIA/GJ/IND2/29678/2018 dated 30/04/19 for obtaining Environmental Clearance.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Toxicological Profile for Carbon Tetrachloride
    CARBON TETRACHLORIDE 27 3. HEALTH EFFECTS 3.1 INTRODUCTION The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and other interested individuals and groups with an overall perspective on the toxicology of carbon tetrachloride. It contains descriptions and evaluations of toxicological studies and epidemiological investigations and provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health. A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE To help public health professionals and others address the needs of persons living or working near hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, developmental, genotoxic, and carcinogenic effects). These data are discussed in terms of three exposure periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). Levels of significant exposure for each route and duration are presented in tables and illustrated in figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest­ observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, or those whose significance to the organism is not entirely clear.
    [Show full text]
  • Alcool Expertise Collective Alcool Effets Sur La Santé Effets Sur La Santé
    Expertise collective Alcool Expertise collective Alcool Effets sur la santé Effets sur la santé Les effets de l’alcool sur la santé font aujour- d’hui encore l’objet d’une importante recherche. Les travaux nous apprennent que ces effets dépendent non seulement des niveaux de consommation, mais également de la suscepti- bilité du consommateur et de ses modalités de consommation. Effets cardiovasculaires délé- tères ou bénéfiques, cancers, hépatopathies, atteintes des systèmes nerveux central ou péri- phérique, toutes les conséquences d’une consommation d’alcool ont été passées au crible dans le cadre de cette expertise collective de l’Inserm effectuée à la demande de la Cnamts, du CFES et de la Mildt. Comment traduire les données récentes en Effets sur la santé termes d’information et de messages de préven- tion ? Les conclusions de cette expertise invitent à adapter ces messages aux différentes popula- tions (jeunes, adultes, personnes âgées) et aux situations particulières (femmes enceintes, Alcool conduite automobile, professions à risque, situations sanitaires à risque…). Prix 180 FF € 27,44 Expertise collective ISBN 2-85598-797-0 ISSN 1264-1782 www.inserm.fr Cet ouvrage présente les travaux du groupe d’experts réunis par l’Inserm dans le cadre de la procédure d’expertise collective, pour répondre aux questions posées par le Comité français d’éducation pour la santé (CFES), la Caisse nationale d’assurance maladie des travailleurs salariés (Cnamts) et la Mission interministérielle de lutte contre la drogue et la toxicomanie (Mildt) concer- nant les effets de la consommation d’alcool sur la santé. Il s’appuie sur les données scientifiques disponibles en date du premier semes- tre 2001.
    [Show full text]
  • Drug Delivery System for Use in the Treatment Or Diagnosis of Neurological Disorders
    (19) TZZ __T (11) EP 2 774 991 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.09.2014 Bulletin 2014/37 C12N 15/86 (2006.01) A61K 48/00 (2006.01) (21) Application number: 13001491.3 (22) Date of filing: 22.03.2013 (84) Designated Contracting States: • Manninga, Heiko AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 37073 Göttingen (DE) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO •Götzke,Armin PL PT RO RS SE SI SK SM TR 97070 Würzburg (DE) Designated Extension States: • Glassmann, Alexander BA ME 50999 Köln (DE) (30) Priority: 06.03.2013 PCT/EP2013/000656 (74) Representative: von Renesse, Dorothea et al König-Szynka-Tilmann-von Renesse (71) Applicant: Life Science Inkubator Betriebs GmbH Patentanwälte Partnerschaft mbB & Co. KG Postfach 11 09 46 53175 Bonn (DE) 40509 Düsseldorf (DE) (72) Inventors: • Demina, Victoria 53175 Bonn (DE) (54) Drug delivery system for use in the treatment or diagnosis of neurological disorders (57) The invention relates to VLP derived from poly- ment or diagnosis of a neurological disease, in particular oma virus loaded with a drug (cargo) as a drug delivery multiple sclerosis, Parkinsons’s disease or Alzheimer’s system for transporting said drug into the CNS for treat- disease. EP 2 774 991 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 774 991 A1 Description FIELD OF THE INVENTION 5 [0001] The invention relates to the use of virus like particles (VLP) of the type of human polyoma virus for use as drug delivery system for the treatment or diagnosis of neurological disorders.
    [Show full text]
  • Metadoxine in the Treatment of Acute and Chronic Alcoholism: a Review
    INTERNATIONAL JOURNAL OF IMMUNOI'ATIIOLOGY AND I'IIARMACOLOGY Vol. 16, no. 3, 207·214 (2003) REVIEWARTICLE METADOXINE IN THE TREATMENT OF ACUTE AND CHRONIC ALCOHOLISM: A REVIEW G. ADDOLORATO, C. ANCONA, E. CAPRISTO and G. GASBARRINI Institute ofInternal Medicine, Catholic University ofRome, Italy Received February 27, 2003 - Accepted August 5, 2003 Alcohol abuse and alcoholism are responsible for a wide variety of medical problems. The pharmaco­ therapeutic aspect of alcoholism includes the use of drugs, with different actions and objectives. Among them, metadoxine seems to be of interest. Metadoxine is able to accelerate the elimination of alcohol from the blood and tissues, to help restore the functional structure of the liver and to relieve neuro-psychological disorders associated with alcohol intoxication. Metadoxine also seems to be safe; in more than 15 years of post-marketing surveillance only minor aspecific and reversible events were monitored in patients exposed to the treatment. In this review the preclinical and clinical results obtained using metadoxine in acute and chronic alcohol intoxication are reported. Alcoholism is a multifactorial disorder in which major contributing factors to road accidents, suicide biologic and genetic factor interact along withcultural and violent death in young adults (11). and social factors (1,2). Alcohol addiction represents The pharmaco-therapeutic aspect of alcoholism a social problem and a relatively common disease of includes the use of drugs, with different actions and western countries like Europe and the USA. From 20 objectives (12). Among them, metadoxine seems to to 40% of subjects admitted to hospitals have alcohol­ be of interest. The present review evaluates the related problems (3) and in elderly people alcohol­ pharmacology and the therapeutic use ofmetadoxine related disorders represent as frequent a reason for (figure I), a drug promoted for the treatment of acute hospitalization as myocardial infarction (4).
    [Show full text]